Insights on increasing the translational value of your preclinical development program.
Nov 3, 2026by MD Biosciences
Remyelination trials in multiple sclerosis are judged on imaging and functional endpoints because myelin cannot be...
Oct 27, 2026by MD Biosciences
Pain is a principal presenting symptom of rheumatoid arthritis, and persistent pain despite low inflammatory activity...
Oct 20, 2026by MD Biosciences
The clinical value of a non-opioid analgesic is defined relative to the established agents it is intended to replace,...
Oct 13, 2026by MD Biosciences
Multiple sclerosis therapy has been transformed by agents that control inflammation, and the unmet need has shifted...
Oct 6, 2026by MD Biosciences
The FDA issued draft guidance on the development of non-opioid analgesics for acute pain in 2022, covering development...
.png?width=1330&height=748&name=Webinar%20Socials%20(8).png)
.png?width=1332&height=748&name=Webinar%20Socials%20(5).png)
.png?width=800&height=924&name=POP%20in%20pigs%20webinar%20(1).png)
